Соединенные Штаты - английский - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 16.1 g - prepopik® is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. prepopik is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute) which may result in accumulation of magnesium [see warnings and precautions (5.4)] - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)] - bowel perforation [see warnings and precautions (5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any of the ingredients in prepopik [see adverse reactions (6.2)] risk summary there are no data with prepopik use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in an animal reproduction study, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1

Соединенные Штаты - английский - NLM (National Library of Medicine)

citra labs llc - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl), trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl) - dextrose monohydrate 0.245 g in 10 ml - anticoagulant citrate dextrose solution, solution a, u.s.p. (acd-a), is intended for use as an anticoagulant in the extracorporeal blood processing with autologous prp systems in production of platelet rich plasma (prp). refer to the manufacturer's operator's manual of the autologous prp system for the directions for use. not for direct intravenous infusion

Соединенные Штаты - английский - NLM (National Library of Medicine)

pai holdings, llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 1100 mg in 5 ml - potassium citrate and citric acid oral solution usp is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. this product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. it is highly palatable, pleasant tasting and tolerable, even when administered for l

Соединенные Штаты - английский - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 160 ml - clenpiq is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. clenpiq is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute), which may result in accumulation of magnesium [see warnings and precautions (5.3)]. - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)]. - bowel perforation [see warnings and precautions (5.6)]. - toxic colitis or toxic megacolon. - gastric retention. - hypersensitivity to any of the ingredients in clenpiq [see adverse reactions (6.2)]. risk summary there are no data with clenpiq use in pregnant women to determine a drug-associated risk of adverse developmental outcomes. in animal reproduction studies, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1.2 times the recommended human dose based

Соединенные Штаты - английский - NLM (National Library of Medicine)

terumo bct, ltd - trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl) - sodium citrate 4% w/v anticoagulant solution is intended for use only for the anticoagulation of whole blood as part of automated apheresis procedures. [see dosage and administration (2).] do not infuse sodium citrate 4% w/v anticoagulant solution usp directly to the donor. sodium citrate 4% w/v anticoagulant solution usp has not been adequately studied in controlled clinical trials with specific populations.

Соединенные Штаты - английский - NLM (National Library of Medicine)

westminster pharmaceuticals, llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), sodium citrate, unspecified form (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate, sodium citrate and citric acid oral solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders. this product is highly concentrated and when administered after meals and before bedtime, allows one to maintain an alkaline urine ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in recommended dosages. it is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. potassium citrate and sodium citrate do not neutralize the gastric juice or disturb digestion. severe renal impairment with ol

Соединенные Штаты - английский - NLM (National Library of Medicine)

haemonetics corporation - citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl), trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr), anhydrous dextrose (unii: 5sl0g7r0ok) (anhydrous dextrose - unii:5sl0g7r0ok) - anhydrous citric acid 32.7 mg in 1 ml - for use with haemonetics apheresis devices rx only the haemonetics 250ml anticoagulant citrate phosphate double dextrose (cp2d) and 250ml additive solution formula 3 (as-3) nutrient solution are intended to be used only with automated apheresis devices for collecting human blood and blood components. the anticoagulant solution is metered by the apheresis machine into the collected whole blood. it is not to be infused directly into the donor. after the anticoagulant is used, the bag in which it was contained is discarded. when collecting plasma in the rbcp protocol, the plasma is collected into an empty plasma collection bag. one hundred milliliters (100ml) of as-3 is transferred into one rbc collection bag when using the rbcp protocol or 2 separate bags when using the

Соединенные Штаты - английский - NLM (National Library of Medicine)

alva-amco pharmacal companies, inc. - trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl), dextrose (unii: iy9xdz35w2) (dextrose - unii:iy9xdz35w2), fructose (unii: 6yss42vsev) (fructose - unii:6yss42vsev) - trisodium citrate dihydrate .921 g in 15 ml - for the relief of nausea associated with upset stomach, including that due to overindulgence in food or drink. do not use if you have hereditary fructose intolerance (hfi).  this product contains fructose. - you have diabetes because this product contains sugar - are on a sodium-restricted diet. stop use and ask a doctor if nausea lasts more than two weeks or recurs frequently.

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - glucose monohydrate; citric acid anhydrous; potassium chloride; sodium citrate dihydrate; sodium chloride - granules for oral solution - 3.58gram ; 128mg ; 300mg ; 390mg ; 470mg

Соединенные Штаты - английский - NLM (National Library of Medicine)

haemonetics manufacturing inc - sodium citrate (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl) - for use with automated plasmapheresis equipment only. use according to equipment manufacturer’s instructions. this unit should be used for plasmapheresis only. not for direct intravenous infusion.